Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Lipocine (LPCN), …
Lipocine (NASDAQ:LPCN) is down 35.5% after receiving a complete response letter (CRL) from the FDA for its testosterone treatment TLANDO.
Odds of approval for LPCN’s Tlando come May 8th? H.
While Lipocine investors run for the hills following negative advisory committee meeting, Canaccord’s Dewey Steadman still sees a light at the end of the tunnel.
Lipocine Inc (NASDAQ:LPCN) failed to convince the Food and Drug Administration advisory committee that its phase 3 data testing TLANDO in hypogonadal male …
Canaccord’s Dewey Steadman says once LPCN’s Tlando gets the safety data it needs in hand to impress the FDA, a green light will flash.
Analysts are eager to weigh in on biotech giant Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) after new earnings results and Lipocine Inc.